1.29
+0.015(+1.18%)
Currency In USD
| Previous Close | 1.27 |
| Open | 1.26 |
| Day High | 1.3 |
| Day Low | 1.25 |
| 52-Week High | 3.48 |
| 52-Week Low | 0.83 |
| Volume | 852,607 |
| Average Volume | 2.97M |
| Market Cap | 92.77M |
| PE | -0.61 |
| EPS | -2.1 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 1.5 |
| Change | 0.02 |
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
GlobeNewswire Inc.
Oct 07, 2025 11:00 AM GMT
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Sep 26, 2025 11:05 AM GMT
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focus
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
GlobeNewswire Inc.
Sep 26, 2025 11:00 AM GMT
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated patients Revita procedure demons